Related Experiment Video
Updated: Jul 12, 2025
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
Published on: January 7, 2019
Genomic insights into the mechanisms of FGFR1 dependency in squamous cell lung cancer
Netta Mäkinen1,2, Matthew Meyerson1,2,3
1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Abstract:
Although subsets of patients with lung squamous cell carcinoma (LSCC) benefit from immunotherapy, there are few effective molecularly targeted treatments for LSCC. Fibroblast growth factor receptor (FGFR) inhibitors provide a therapeutic option for patients with LSCC harboring FGFR aberrations, but their therapeutic efficacy has been limited to date. In this issue of the JCI, Malchers et al. identified tail-to-tail rearrangements, either within or near FGFR1, that are associated with FGFR1 dependency and sensitivity to FGFR inhibition in LSCC. These results may help improve the selection of patients with LSCC who are most likely to benefit from treatment with FGFR inhibitors.
Insights
New findings reveal tail-to-tail rearrangements near FGFR1 in lung squamous cell carcinoma (LSCC). These genetic alterations predict sensitivity to fibroblast growth factor receptor (FGFR) inhibitors, potentially improving targeted therapy selection for LSCC patients.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Lung squamous cell carcinoma (LSCC) has limited targeted treatment options beyond immunotherapy.
- Fibroblast growth factor receptor (FGFR) inhibitors show promise for LSCC with FGFR aberrations, but efficacy is often restricted.
Discussion:
- Identified specific tail-to-tail rearrangements involving FGFR1 in LSCC.
- These rearrangements lead to FGFR1 dependency and sensitivity to FGFR inhibitors.
- This discovery offers a potential biomarker for treatment selection.
Key Insights:
- Tail-to-tail rearrangements within or near FGFR1 are crucial in LSCC.
- FGFR1 dependency driven by these rearrangements predicts response to FGFR inhibitors.
- This provides a molecular basis for targeted therapy in a subset of LSCC patients.
Outlook:
- Potential for improved patient stratification for FGFR inhibitor therapy in LSCC.
- Further research may elucidate the precise mechanisms of FGFR1 dependency.
- Development of novel diagnostic tools to detect these specific rearrangements.
More Related Videos
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
07:48Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures
Published on: December 26, 2016
